Intervention
irinotecan hydrochloride
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 37 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
37 shownA Pilot Study of Irinotecan in Patients With Breast Cancer and CNS MetastasesNCT01939483 · 2012-12-01
WITHDRAWNSunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by SurgeryNCT00936832 · 2009-04-01
WITHDRAWNCetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or LungNCT00557102 · 2007-09-01
COMPLETEDCombination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT00616785 · 2007-06-01
UNKNOWNCombination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by SurgeryNCT00513266 · 2007-06-01
UNKNOWNIrinotecan and Cetuximab in Treating Patients With Metastatic Breast CancerNCT00275041 · 2006-02-01
COMPLETEDIrinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain MetastasesNCT00617539 · 2005-02-01
COMPLETEDCisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerNCT00118235 · 2004-12-01
COMPLETEDIrinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung CancerNCT00182806 · 2004-09-01
COMPLETEDTrastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast CancerNCT00303992 · 2004-05-01
COMPLETEDAmrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung CancerNCT00132054 · 2004-05-01
COMPLETEDIrinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast CancerNCT00079118 · 2004-04-01
COMPLETEDCarboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung CancerNCT00449020 · 2004-01-01
COMPLETEDIrinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00469898 · 2003-12-01
COMPLETEDCisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00072527 · 2003-11-01
COMPLETEDCombination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung CancerNCT00073866 · 2003-06-01
COMPLETEDIrinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung CancerNCT00104793 · 2003-06-01
COMPLETEDCombination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00052494 · 2003-04-01
COMPLETEDChemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00059761 · 2003-03-01
COMPLETEDNeoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00062322 · 2003-02-01
COMPLETEDS0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung CancerNCT00045162 · 2002-11-01
COMPLETEDIrinotecan and Capecitabine in Treating Women With Advanced Breast CancerNCT00083148 · 2002-11-01
COMPLETEDUCN-01 and Irinotecan in Treating Patients With Advanced Solid TumorsNCT00047242 · 2002-08-01
COMPLETEDImatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00045604 · 2002-07-01
COMPLETEDS0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00030433 · 2002-01-01
COMPLETED7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01
COMPLETEDCombination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00025285 · 2001-11-01
COMPLETEDCombination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung CancerNCT00005972 · 2000-05-01
COMPLETEDIrinotecan in Treating Patients With Metastatic or Recurrent Breast CancerNCT00004182 · 1999-10-01
COMPLETEDIrinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung CancerNCT00003900 · 1999-10-01
COMPLETEDGemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerNCT00004139 · 1999-09-01
COMPLETEDIrinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid TumorsNCT00004095 · 1999-08-01
COMPLETEDIrinotecan and Capecitabine in Treating Patients With Solid TumorsNCT00003867 · 1999-03-01
COMPLETEDPaclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung CancerNCT00004924 · 1999-03-01
COMPLETEDChemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerNCT00022308 · 1999-01-01
COMPLETEDIrinotecan in Treating Patients With Refractory Metastatic Breast CancerNCT00003351 · 1998-08-01
COMPLETEDCombination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung CancerNCT00003111 · 1997-04-01
COMPLETEDCommon conditions
Lung Cancer22Breast Cancer8Colorectal Cancer4Metastatic Cancer4Extensive Stage Small Cell Lung Cancer2Recurrent Breast Cancer2Stage IV Breast Cancer2Unspecified Adult Solid Tumor, Protocol Specific2Advanced Adult Primary Liver Cancer1Bladder Cancer1Cancer1Carcinoma of the Appendix1Central Nervous System Metastases1Estrogen Receptor-negative Breast Cancer1Gastrointestinal Stromal Tumor1HER2-negative Breast Cancer1Kidney Cancer1Male Breast Cancer1Metastatic Gastrointestinal Carcinoid Tumor1Ovarian Sarcoma1Ovarian Stromal Cancer1Pancreatic Cancer1Progesterone Receptor-negative Breast Cancer1Recurrent Adenoid Cystic Carcinoma of the Oral Cavity1Recurrent Adult Primary Liver Cancer1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
lung cancer22breast cancer8colorectal cancer4metastatic malignant neoplasm4appendix carcinoma1cancer1estrogen-receptor negative breast cancer1gastrointestinal stromal tumor1kidney cancer1male breast carcinoma1malignant epithelial tumor of ovary1malignant pancreatic neoplasm1ovarian sarcoma1progesterone-receptor negative breast cancer1small intestine adenocarcinoma1small intestine leiomyosarcoma1small intestine lymphoma1triple-negative breast carcinoma1
Leading sponsors
Alliance for Clinical Trials in Oncology
7
Northwestern University
3
Fox Chase Cancer Center
2
Japan Multinational Trial Organization
2
National Cancer Institute (NCI)
2
Roswell Park Cancer Institute
2
SWOG Cancer Research Network
2
University of California, San Francisco
2
Yale University
2
Centre Hospitalier Universitaire Vaudois
1
Federation Francophone de Cancerologie Digestive
1
Memorial Sloan Kettering Cancer Center
1
Montefiore Medical Center
1
National Cancer Institute, France
1
Radiation Therapy Oncology Group
1
Trial status mix
COMPLETED33
UNKNOWN2
WITHDRAWN2
Phase mix
PHASE224
PHASE112
NA1
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.